These include luminal A (ER+, PR+), luminal B (ER/PR+, HER2+), HER2+, and basal-type breast cancer or triple-negative breast cancer (TNBC) with the absence of mentioned receptors [2]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.